Using autoantibodies to diagnose systemic autoimmune diseases triggered by immune checkpoint inhibitors: a clinical perspective.

Show simplified metadata
dc.contributor.authorFlores-Chávez, Alejandra
dc.contributor.authorBrito-Zerón, Pilar
dc.contributor.authorRetamozo, Soledad
dc.contributor.authorBitoun, Samuel
dc.contributor.authorFisher, Benjamin A
dc.contributor.authorLiew, David
dc.contributor.authorSuijkerbuijk, Karijn
dc.contributor.authorChatzidionysiou, Katerina
dc.contributor.authorSuárez-Almazor, María
dc.contributor.authorLambotte, Olivier
dc.contributor.authorMariette, Xavier
dc.contributor.authorRamos-Casals, Manuel
dc.contributor.departmentRheumatologyen_US
dc.contributor.roleMedical and Dentalen_US
dc.contributor.trustauthorFisher, Ben
dc.date.accessioned2024-10-15T14:03:25Z
dc.date.available2024-10-15T14:03:25Z
dc.date.issued2022
dc.description.abstractImmunotherapies, such as immune checkpoint inhibitors (ICIs), have significantly advanced the treatment of cancer and other conditions. However, these therapies can also cause immune-related adverse events (irAEs), which are unintended side effects due to their effects on the immune system of the treated patient. These effects can be classified as organ-specific or systemic, with the latter being of particular interest due to their potential overlap with systemic autoimmune diseases (SADs). Autoantibodies, which are proteins produced by the immune system that react with self components, are often used to diagnose and classify SAD. However, the diagnostic value of autoantibodies in the context of systemic irAEs (sirAEs) triggered by ICIs is not well understood. This review aims to evaluate the diagnostic value of conventional autoantibodies in the identification and classification of sirAEs. A comprehensive search of the literature was conducted using the PubMed database, with a focus on articles published in the past 10 years. The results of the review suggest that, although autoantibodies can be useful in the diagnosis and classification of some SAD triggered by ICIs, there is a clear predominance of seronegative irAEs. The lack of traditional autoantibodies may suggest a unique mechanism for sirAEs and increases the already complex diagnostic approach of these manifestations, requiring evaluation by multidisciplinary teams with extensive experience in immunomediated diseases. Further research is needed to fully understand the diagnostic value of autoantibodies in this context and to determine the optimal approach for their detection and interpretation.en_US
dc.identifier.citationFlores-Chávez A, Brito-Zerón P, Retamozo S, Bitoun S, Fisher BA, Liew D, Suijkerbuijk K, Chatzidionysiou K, Suárez-Almazor M, Lambotte O, Mariette X, Ramos-Casals M. Using Autoantibodies to Diagnose Systemic Autoimmune Diseases Triggered by Immune Checkpoint Inhibitors: A Clinical Perspective. Crit Rev Immunol. 2022;42(4):21-36. doi: 10.1615/CritRevImmunol.2023047272en_US
dc.identifier.doi10.1615/CritRevImmunol.2023047272
dc.identifier.issn1040-8401
dc.identifier.pmid37022357
dc.identifier.urihttp://hdl.handle.net/20.500.14200/6127
dc.language.isoenen_US
dc.publisherBegell Houseen_US
dc.relation.urlhttp://www.begellhouse.com/journals/critical-reviews-in-immunology.htmlen_US
dc.source.beginpage21
dc.source.countryUnited States
dc.source.endpage36
dc.source.issue4
dc.source.journaltitleCritical Reviews in Immunologyen_US
dc.source.volume42
dc.subjectRheumatologyen_US
dc.titleUsing autoantibodies to diagnose systemic autoimmune diseases triggered by immune checkpoint inhibitors: a clinical perspective.en_US
dc.typeArticleen_US
dc.typeOtheren_US
dspace.entity.typePublication
oa.grant.openaccessnaen_US
rioxxterms.versionNAen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.7 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Rheumatology